Upon this dosing schedule, tumor tissues showed a normalized vasculature, as manifested by a reduced vessel density, increased pericyte and basement membrane coverage, and improved tumor vasculature, as shown by vessel reconstruction, and increased expression of EC junctional proteins VE-cadherin and ZO-1 (Figure 10, E and F). The gene discussed is CDH5; the disease is neoplasm.